We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunization with a recombinant GnRH vaccine fused to heat shock protein 65 inhibits mammary tumor growth in vivo.
- Authors
Xue Jun Wang; Kai Gu; Jin Shu Xu; Ming Hui Li; Rong Yue Cao; Jie Wu; Tai Ming Li; Jing Jing Liu
- Abstract
Gonadotrophin-releasing hormone (GnRH) is the prime decapeptide hormone in the regulation of mammalian reproduction. Active immunization against GnRH has been a good treatment option to fight against hormone-dependent disease such as breast cancer. We designed and purified a novel protein vaccine Hsp65-GnRH containing heat shock protein 65 (Hsp65) and six copies of GnRH in linear alignment. Immunization with Hsp65-GnRH evoked strong humoral response in female mice. The generation of specific anti-GnRH antibodies was detected by ELISA and verified by western blot. In addition, anti-GnRH antibodies effectively neutralized endogenous GnRH activity in vivo, as demonstrated by the degeneration of the ovaries and uteri in the vaccinated mice. Moreover, the growth of EMT-6 mammary tumor allografts was inhibited by anti-GnRH antibodies. Histological examinations have shown that there was increased focal necrosis in tumors. Taken together, our results showed that immunization with Hsp65-GnRH elicited high titer of specific anti-GnRH antibodies and further led to atrophy of reproductive organs. The specific antibodies could inhibit the growth of EMT-6 murine mammary tumor probably via an indirect mechanism that includes the depletion of estrogen. In view of these results, the protein vaccine Hsp65-GnRH appears to be a promising candidate vaccine for hormone-dependent cancer therapy.
- Subjects
GONADOTROPIN releasing hormone; ENZYME-linked immunosorbent assay; IMMUNIZATION; IMMUNOGLOBULINS; GENITALIA
- Publication
Cancer Immunology, Immunotherapy, 2010, Vol 59, Issue 12, p1859
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-010-0911-4